CAEL-101: a monoclonal antibody therapy for AL amyloidosis

CAEL-101: a monoclonal antibody therapy for AL amyloidosis

Advancing amyloidosis care: developments in anti-amyloid monoclonal antibodiesПодробнее

Advancing amyloidosis care: developments in anti-amyloid monoclonal antibodies

Update on CAEL-101 from Caelum BiosciencesПодробнее

Update on CAEL-101 from Caelum Biosciences

CAEL-101 UpdateПодробнее

CAEL-101 Update

CAEL-101: una terapia de anticuerpo monoclonal para amiloidosis primariaПодробнее

CAEL-101: una terapia de anticuerpo monoclonal para amiloidosis primaria

Updates in amyloidosis at ASH 2020Подробнее

Updates in amyloidosis at ASH 2020

CAEL-101 ASH Annual Meeting December 2020 Oral PresentationПодробнее

CAEL-101 ASH Annual Meeting December 2020 Oral Presentation

ARC Talks: Contemporary Management of AL AmyloidosisПодробнее

ARC Talks: Contemporary Management of AL Amyloidosis

CAEL-101 ASH Annual Meeting December 2020 Poster PresentationПодробнее

CAEL-101 ASH Annual Meeting December 2020 Poster Presentation

A Phase 2, Open-Label Study - Safety, Tolerability and Efficacy of Cael-101 in AL Amyloidosis PtsПодробнее

A Phase 2, Open-Label Study - Safety, Tolerability and Efficacy of Cael-101 in AL Amyloidosis Pts